At 6.7% CAGR, the Middle East & Africa Antimicrobial Surgical Suture Market is Projected to be Worth US$ 18.07 Million by 2031, Says Business Market Insights

According to Business Market Insights' research, the Middle East & Africa antimicrobial surgical suture market was valued at US$ 10.80 in 2023 and is expected to reach US$ 18.07 million by 2031, registering a CAGR of 6.7% from 2024–2031. Smart antimicrobial sutures and strategic initiatives in antimicrobial surgical suture are among the critical factors attributed to the Middle East & Africa antimicrobial surgical suture market expansion.

The RMIT Centre for Materials Innovation and Future Fashion is one of the organizations focusing on developing new, smart antimicrobial sutures to reduce the prevalence of surgical site infections. The center's suture products are made from materials that glow during medical imaging procedures; these stitches have the potential to replace mesh implants as promising alternatives. They can be beneficial in monitoring patient recovery progress, in addition to their impressive antimicrobial properties, preventing infections and killing 99% of highly drug-resistant bacteria after 6 hours of contact at body temperature. It may also significantly reduce surgery duration and increase surgical accuracy in general through the ability to visualize mesh location accurately on preoperative imaging.

MIT engineers have created "smart" sutures that can not only hold tissues in place but also sense inflammation and deliver drugs. The new sutures are made from animal tissue, similar to the "catgut" sutures created by the ancient Romans. These sutures are coated with hydrogels that can be integrated with sensors, drugs, or even cells that release therapeutic substances. These sutures could be particularly beneficial for the treatment of Crohn's disease patients who need to undergo colectomy due to excessive scarring or inflammation. MIT's smart sutures hold the tissue in place and identify inflammation as an early warning sign indicating the improper functioning of the resealed intestines. The hydrogel coating of these sutures carries drugs through microparticles composed of FDA-approved polymers such as PLA and PLGA, which also aid in a controlled drug release rate. This approach could also be used to deliver other drugs, such as chemotherapy drugs or antibiotics. Therefore, developments in smart antimicrobial surgical sutures are expected to bring new growth trends in the antimicrobial surgical sutures market growth in the coming years.

On the contrary, non-invasive alternatives to stitches hamper the growth of Middle East & Africa antimicrobial surgical suture market.

Based on type, the Middle East & Africa antimicrobial surgical suture market is bifurcated into triclosan antimicrobial suture and chlorhexidine antimicrobial suture. The triclosan antimicrobial suture segment held 71.7% share of the Middle East & Africa antimicrobial surgical suture market in 2023, amassing US$ 7.74 million. It is projected to garner US$ 13.12 million by 2031 to expand at 6.9% CAGR during 2024–2031.

By raw materials, the Middle East & Africa antimicrobial surgical suture market is segmented into polyglactin 910 antimicrobial suture, poliglecaprone 25, and polyglycolic acid. The polyglactin 910 antimicrobial suture segment held 60.3% share of the Middle East & Africa antimicrobial surgical suture market in 2023, amassing US$ 6.51 million. It is projected to garner US$ 10.92 million by 2031 to expand at 6.7% CAGR during 2024–2031.

By application, the Middle East & Africa antimicrobial surgical suture market is segmented into cardiovascular surgery, general surgery, ophthalmic surgery, gynecological surgery, orthopedic surgery, plastic surgery, veterinary surgery, dental surgery, and others. The cardiovascular surgery segment held 33.2% share of the Middle East & Africa antimicrobial surgical suture market in 2023, amassing US$ 3.59 million. It is projected to garner US$ 5.81 million by 2031 to expand at 6.3% CAGR during 2024–2031.

By end user, the Middle East & Africa antimicrobial surgical suture market is segmented into hospitals, ambulatory surgical centers, and others. The hospitals surgery segment held a 46.4% share of the Middle East & Africa antimicrobial surgical suture market in 2023, amassing US$ 5.01 million. It is projected to garner US$ 8.22 million by 2031 to expand at 6.4% CAGR during 2024–2031.

Based on country, the Middle East & Africa antimicrobial surgical suture market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Saudi Arabia held 33.9% share of Middle East & Africa antimicrobial surgical suture market in 2023, amassing US$ 3.66 million. It is projected to garner US$ 6.03 million by 2031 to expand at 6.5% CAGR during 2024–2031.

Key players operating in the Middle East & Africa antimicrobial surgical suture market are Advanced MedTech Solutions Pvt. Ltd.; Boz Medical; Futura Surgicare Pvt Ltd (Dolphin Sutures); Healthium Medtech Limited; Internacional Farmacéutica SA; Johnson & Johnson; Meril Life Sciences Pvt Ltd; and TI Medical, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com